AC
TBPH icon

Armistice Capital’s Theravance Biopharma TBPH Stock Holding History

Armistice Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,180,000
Closed -$26.8M – 90
2018
Q2 		$26.8M Buy
+1,180,000
New +$28M 1.75% 26
2016
Q2 		– Sell
-400,000
Closed -$7.52M – 50
2016
Q1 		$7.52M Buy
+400,000
New +$6.54M 2.95% 12
2015
Q3 		– Sell
-974,000
Closed -$12.7M – 42
2015
Q2 		$12.7M Buy
974,000
+462,000
+90% +$7.17M 4.56% 9
2015
Q1 		$8.88M Buy
+512,000
New +$9.39M 3.94% 10

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Armistice Capital's TBPH Position: Q3 2018 in Review

Armistice Capital sold out of Theravance Biopharma (TBPH) in Q3 2018, closing a stake of 1,180,000 shares — an estimated $26.8M sold.

Armistice Capital first reported a position in TBPH in Q1 2015 and held it in 4 quarters. The position peaked at $26.8M in Q2 2018. 93 funds tracked by Wall St. Rank hold TBPH as of Q3 2018.

  • Armistice Capital reported no remaining Theravance Biopharma position as of Q3 2018 after selling out during the quarter.
  • Armistice Capital sold 1,180,000 Theravance Biopharma shares in Q3 2018, an estimated $26.8M.
  • Armistice Capital first reported a position in Theravance Biopharma in Q1 2015 and held it in 4 quarters.
  • Armistice Capital's Theravance Biopharma position peaked at $26.8M in Q2 2018.
  • 93 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2018.

Based on Armistice Capital's 13F filing for Q3 2018, filed 14 Nov 2018.